Nexstim Oyj
Company announcement, inside information, Helsinki, 8 March 2021 at 3.15 PM (EET)
Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issue
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces with reference to the company announcement published earlier today regarding a subscription rights issue totaling approximately EUR 6.6 million , that the Company has prepared an EU growth prospectus which the Finnish Financial Supervisory Authority (FIN-FSA) has approved on 8 March 2021. The Board of Directors of Nexstim has resolved to publish the EU growth prospectus on 8 March 2021 and it shall be notified to Sweden.
Finnish version of the EU growth Prospectus will be available approximately on 8 March 2021 on the Nexstim’s website at http://www.nexstim.com/investors/rights-issue-2021 and at the registered office of the Company at Elimäenkatu 9 B, 00510 Helsinki. Moreover, the Finnish version of the EU growth prospectus will be available at the reception of the Nasdaq Helsinki Office at Fabianinkatu 14, 00100 Helsinki.
The EU growth prospectus in English and summary in Swedish will be available on Nexstim’s website at http://www.nexstim.com/investors/rights-issue-2021 approximately on 8 March 2021.
NEXSTIM PLC
Leena Niemistö, Chair of the Board of Directors
Further information is available on the website www.nexstim.com, or by contacting:
Leena Niemistö, Chair
+358 9 2727 170
leena.niemisto@nexstim.com
Erik Penser Bank AB (Certified Adviser)
+46 8 463 83 00
certifiedadviser@penser.se
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Netbet Enterprises Limited26.4.2024 11:34:38 CEST | Press release
NetBet Casino joins forces with Habanero
Netbet Enterprises Limited26.4.2024 11:34:38 CEST | Pressemeddelelse
NetBet Casino slår sig sammen med Habanero
Boehringer Ingelheim25.4.2024 09:01:09 CEST | Press release
Less than half of veterinary professionals feel their profession is appreciated
TrueCommerce23.4.2024 19:11:45 CEST | Pressemeddelelse
TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse
TrueCommerce23.4.2024 12:01:08 CEST | Press release
TrueCommerce Delivers Global E-Invoicing and CTC Solution for Businesses Facing Compliance Challenges
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom